Published in Stem Cells Dev on December 20, 2013
Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle. Stem Cells (2015) 0.82
In situ normoxia enhances survival and proliferation rate of human adipose tissue-derived stromal cells without increasing the risk of tumourigenesis. PLoS One (2015) 0.81
Failure of intravenous or intracardiac delivery of mesenchymal stromal cells to improve outcomes after focal traumatic brain injury in the female rat. PLoS One (2015) 0.79
A new method of wound treatment: targeted therapy of skin wounds with reactive oxygen species-responsive nanoparticles containing SDF-1α. Int J Nanomedicine (2015) 0.78
Preconditioning of bone marrow mesenchymal stem cells with hydrogen sulfide improves their therapeutic potential. Oncotarget (2016) 0.76
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol (2007) 14.48
Mesenchymal stem cells as trophic mediators. J Cell Biochem (2006) 9.38
The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med (2013) 4.32
Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev (2009) 3.73
Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev (2009) 3.43
Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells (2008) 3.12
Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res (2007) 2.98
Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg (2008) 2.87
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun (2007) 2.67
Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem (2009) 2.66
A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells (2010) 2.50
Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells (2005) 2.37
Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem (1999) 2.17
Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One (2007) 2.06
Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am J Physiol Cell Physiol (2005) 1.76
Hypoxic preconditioning enhances angiogenic potential of bone marrow cells with aging-related functional impairment. Circ J (2012) 1.65
Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem Biophys Res Commun (2010) 1.64
The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One (2012) 1.56
Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev (2010) 1.50
Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation (2011) 1.48
Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol (2010) 1.47
Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem (2012) 1.41
Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci (2008) 1.36
Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther (2003) 1.33
Hypoxia preconditioned mesenchymal stem cells improve vascular and skeletal muscle fiber regeneration after ischemia through a Wnt4-dependent pathway. Mol Ther (2010) 1.31
Hypoxia promotes proliferation and osteogenic differentiation potentials of human mesenchymal stem cells. J Orthop Res (2011) 1.27
VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun (2008) 1.26
Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death Differ (2011) 1.23
Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther (2009) 1.21
Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness". PLoS One (2010) 1.20
Preconditioning and stem cell survival. J Cardiovasc Transl Res (2009) 1.17
Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells. Stem Cells Dev (2010) 1.14
Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy (2013) 1.14
Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro. Stem Cells Dev (2012) 1.08
Progenitor cell therapy for heart disease. Exp Cell Res (2009) 1.06
Sex dimorphisms in activated mesenchymal stem cell function. Shock (2006) 1.05
Preconditioning strategy in stem cell transplantation therapy. Transl Stroke Res (2013) 1.01
Spherical bullet formation via E-cadherin promotes therapeutic potency of mesenchymal stem cells derived from human umbilical cord blood for myocardial infarction. Mol Ther (2012) 0.98
Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy. Stem Cell Rev (2013) 0.94
Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection. Stem Cells Transl Med (2013) 0.86
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81
Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology (2003) 3.72
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed (2005) 2.20
Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed (2005) 2.02
In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab (2002) 1.99
Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol (2008) 1.87
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices (2006) 1.71
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res (2006) 1.66
Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells (2005) 1.61
In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther (2004) 1.61
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol (2005) 1.60
Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed (2006) 1.58
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol (2008) 1.56
Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation (2003) 1.55
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging. Nat Med (2012) 1.53
Craniotomy: true sham for traumatic brain injury, or a sham of a sham? J Neurotrauma (2011) 1.49
Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med (2005) 1.48
Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain (2003) 1.43
In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells (2008) 1.41
Neurite beading is sufficient to decrease the apparent diffusion coefficient after ischemic stroke. Proc Natl Acad Sci U S A (2010) 1.40
Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J (2008) 1.36
Temporal dynamics of the BOLD fMRI impulse response. Neuroimage (2004) 1.28
Susceptibility gradient mapping (SGM): a new postprocessing method for positive contrast generation applied to superparamagnetic iron oxide particle (SPIO)-labeled cells. Magn Reson Med (2008) 1.28
Viral capsids as MRI contrast agents. Magn Reson Med (2007) 1.28
Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol (2006) 1.24
Cellular MRI and its role in stem cell therapy. Regen Med (2008) 1.23
Hedgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol (2007) 1.22
Examining brain microstructure using structure tensor analysis of histological sections. Neuroimage (2012) 1.21
Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness". PLoS One (2010) 1.20
Optimization and validation of FePro cell labeling method. PLoS One (2009) 1.19
Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer (2005) 1.19
In vivo MRI using positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide nanoparticles. NMR Biomed (2008) 1.17
Macrophagic and microglial responses after focal traumatic brain injury in the female rat. J Neuroinflammation (2014) 1.14
In Vivo Cellular Imaging for Translational Medical Research. Curr Med Imaging Rev (2009) 1.12
In vivo transfer of intracellular labels from locally implanted bone marrow stromal cells to resident tissue macrophages. PLoS One (2009) 1.12
Magnetic tagging of therapeutic cells for MRI. J Nucl Med (2009) 1.11
Ultrashort T2* relaxometry for quantitation of highly concentrated superparamagnetic iron oxide (SPIO) nanoparticle labeled cells. Magn Reson Med (2009) 1.09
Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. Nano Lett (2009) 1.08
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med (2013) 1.07
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med (2009) 1.03
Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci (2004) 1.02
Stromal-derived factor-1[alpha] correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke (2011) 1.01
EPI-BOLD fMRI of human motor cortex at 1.5 T and 3.0 T: sensitivity dependence on echo time and acquisition bandwidth. J Magn Reson Imaging (2004) 1.00
Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells (2012) 1.00
MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med (2003) 0.98
Imaging approaches for the study of cell-based cardiac therapies. Nat Rev Cardiol (2009) 0.96
Effect of human stem cells labeled with ferumoxides-poly-L-lysine on hematologic and biochemical measurements in rats. Radiology (2005) 0.96
Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain (2005) 0.95
Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI. PLoS One (2010) 0.93
Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis (2011) 0.92
Imaging of spontaneous ventriculomegaly and vascular malformations in Wistar rats: implications for preclinical research. J Neuropathol Exp Neurol (2014) 0.91
Loss of interhemispheric inhibition in patients with multiple sclerosis is related to corpus callosum atrophy. Exp Brain Res (2006) 0.91
P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol Pharm (2012) 0.91
Synthesis of superparamagnetic nanotubes as MRI contrast agents and for cell labeling. Nanomedicine (Lond) (2008) 0.90
In vivo detection of embryonic stem cell-derived cardiovascular progenitor cells using Cy3-labeled Gadofluorine M in murine myocardium. JACC Cardiovasc Imaging (2009) 0.90
Synthesis of Complexable Fluorescent Superparamagnetic Iron Oxide Nanoparticles (FL SPIONs) and Cell Labeling for Clinical Application. Adv Mater (2008) 0.90
Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci Lett (2008) 0.89
Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS One (2011) 0.88
Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect. J Med Food (2012) 0.88
Effects of indomethacin on cerebral blood flow at rest and during hypercapnia: an arterial spin tagging study in humans. J Magn Reson Imaging (2002) 0.88
Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J Agric Food Chem (2013) 0.87
Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad Radiol (2002) 0.86
Pulsed arterial spin labeling: comparison of multisection baseline and functional MR imaging perfusion signal at 1.5 and 3.0 T: initial results in six subjects. Radiology (2002) 0.85
MRI of mouse models of neurological disorders. NMR Biomed (2007) 0.84
The evolution of traumatic brain injury in a rat focal contusion model. NMR Biomed (2012) 0.84
Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients. J Transl Med (2011) 0.84
Magnetically-labeled sensitized splenocytes to identify glioma by MRI: a preliminary study. Magn Reson Med (2007) 0.84
Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice. Stem Cells (2015) 0.83
Rapid spectrophotometric technique for quantifying iron in cells labeled with superparamagnetic iron oxide nanoparticles: potential translation to the clinic. Contrast Media Mol Imaging (2012) 0.83
Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle. Stem Cells (2015) 0.82
Quantitative T2* imaging of metastatic human breast cancer to brain in the nude rat at 3 T. NMR Biomed (2010) 0.81
Fast T(2) relaxometry with an accelerated multi-echo spin-echo sequence. NMR Biomed (2010) 0.81
Pharmacokinetics of a high-generation dendrimer-Gd-DOTA. Acad Radiol (2002) 0.80
The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis. Expert Opin Biol Ther (2008) 0.79
Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo. Chin J Cancer (2013) 0.79
Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain. NMR Biomed (2011) 0.78
Manganese G8 dendrimers targeted to oxidation-specific epitopes: in vivo MR imaging of atherosclerosis. J Magn Reson Imaging (2014) 0.78
Enhanced stem cell tracking via electrostatically assembled fluorescent SPION-peptide complexes. Nanotechnology (2009) 0.78
Lacinutrix jangbogonensis sp. nov., a psychrophilic bacterium isolated from Antarctic marine sediment and emended description of the genus Lacinutrix. Antonie Van Leeuwenhoek (2014) 0.78
β-PIX is critical for transplanted mesenchymal stromal cell migration. Stem Cells Dev (2012) 0.77
Theory and practice of imaging saturable binding sites. Invest Radiol (2002) 0.76
Sigma-2 receptor as potential indicator of stem cell differentiation. Mol Imaging Biol (2012) 0.76
Magnetically labeled glial cells as cellular MR contrast agents. Acad Radiol (2002) 0.76
Comparison of methods for obtaining longitudinal whole-brain magnetization transfer measurements. J Magn Reson Imaging (2002) 0.76
Transferrin receptor expression in iron oxide-labeled mesenchymal stem cells. Radiology (2008) 0.75